Bio-TechneMEX:TECH 83 Net Margin % is 16.39% as of Mar. 2026, which is 6% below its 10-year median of 17.35. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,117.60. The stock has 8 warning signs investors should review. Among 946 Biotechnology companies, Bio-Techne ranks better than 80.44% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Bio-Techne's Net Income for the
three
months ended in Mar. 2026 was MXN921 Mil. Bio-Techne's Revenue for the
three
months ended in Mar. 2026 was MXN5,616 Mil. Therefore, Bio-Techne's net margin for the quarter that ended in Mar. 2026 was 16.39%.
The historical rank and industry rank for Bio-Techne's Net Margin % or its related term are showing as below:
MEX:TECH'
s Net Margin % Range Over the Past 10 Years
Min: 6.02 Med: 17.35 Max: 31.04
Current: 9.05
MEX:TECH's Net Margin % is ranked better than 80.44% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs MEX:TECH: 9.05
Bio-Techne (MEX:TECH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bio-Techne Net Margin % Related Terms
Bio-Techne Net Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs HALO, IBRX, NUVL: Net Margin % Comparison
For the Biotechnology subindustry, Bio-Techne's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (MEX:TECH) has a Net Margin % of 16.39% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Bio-Techne and its competitors. This is near median its historical median of 17.35. Over the past decade, Bio-Techne's Net Margin % has ranged from 6.02 to 31.04. According to the industry distribution chart, Bio-Techne ranks #185 out of 946 companies in the Biotechnology industry, placing it in the top 19.6%.
Is Bio-Techne's Net Margin % too high?
Bio-Techne's current Net Margin % of 16.39% is near median its 10-year median of 17.35. Over the past 10 years, this metric has ranged from a low of 6.02 to a high of 31.04. Based on the distribution chart, Bio-Techne ranks #185 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Net Margin % compare to HALO and IBRX?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #185 out of 946 companies for Net Margin %. This places Bio-Techne in the top 20% of its industry — outperforming the majority of peers. Historically, Bio-Techne's own Net Margin % has ranged from 6.02 to 31.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bio-Techne and its competitors. Bio-Techne's current Net Margin % is 16.39%, which is near median its own 10-year median of 17.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Net Margin % of 16.39%. The stock's GF Value™ is MXN1,117.60, compared to a current price of MXN1,090.00 — trading 2.5% below its estimated fair value. The current Net Margin % is 16.39%, which is near median its 10-year median of 17.35. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Net Margin % is 16.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2.5% below its estimated GF Value™ of MXN1,117.60.
Key valuation signals for MEX:TECH:
Net Margin %: 16.39% (near median its 10-year median of 17.35)
GF Value™: MXN1,117.60 vs. price of MXN1,090.00 (2.5% below fair value)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
